Effect of depressive symptoms on treatment response in patients with axSpA: data from the RABBIT-SpA register
Depressive symptoms have a significant and independent negative effect on treatment response in patients with axSpA, particularly in achieving LDA and ID. These findings highlight the importance of routine mental health screening and treatment of depressive symptoms in axSpA management to optimise disease outcomes.
Authors
- Andreas Reich (ORCID: https://orcid.org/0000-0002-3729-0772)
- Lisa Lindner (ORCID: https://orcid.org/0000-0001-8416-0463)
- Anja Strangfeld (ORCID: https://orcid.org/0000-0002-6233-022X)
- Denis Poddubnyy (ORCID: https://orcid.org/0000-0002-4537-6015)
- Anja Weiß (ORCID: https://orcid.org/0000-0003-2069-2190)
- Carsten Stille
- Xenofon Baraliakos (ORCID: https://orcid.org/0000-0002-9475-9362)
- J. Detert
- Anne C. Regierer (ORCID: https://orcid.org/0000-0003-2456-4049)
- Silke Zinke
Institutions
- Temple College (US)
- Rheumazentrum Ruhrgebiet (DE)
- German Rheumatism Research Centre (DE)
- Hannover Re (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- RMD Open
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-005422
- Citations
- 6
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 10.01
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Biogen
- Hexal AG
- Biocon
- Celltrion Healthcare
- Celltrion
- Lilly Deutschland
- AbbVie Deutschland
- Novartis Pharma
- Cilag